The US Food and Drug Administration (FDA) has granted fast-track designation to AiCuris' Letermovir, an inhibitor of the human cytomegalovirus.
Letermovir is currently being evaluated in an international Phase IIb trial, with efficacy results expected by the end of 2011.
AiCuris CEO Helga Rübsamen-Schaeff said that the fast-track status will hopefully facilitate the regulatory process for the drug and support the company's view that Letermovir has the potential to become the treatment of choice for patients at risk of human cytomegalovirus.
Twitter